GlassScriptPhysician profile
Pedro I Troya
NPI 1427187319
$13,470.18
in general payments reported to CMS, 2019-2025
55 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,223 · 2020: $1,450 · 2021: $2,059 · 2022: $2,361 · 2023: $1,780 · 2024: $1,936 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,376.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,451.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,394.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $1,333.28 | 2019-2024 | |
| Dexcom, INC. | $740.73 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.40 | 2019-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $556.22 | 2019-2025 | Korlym |
| Beta Bionics, INC. | $528.62 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbott Laboratories | $476.52 | 2019-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $429.53 | 2019-2023 | Steglujan, Steglatro |
| Xeris Pharmaceuticals, INC. | $413.51 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $386.32 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.49 | 2019-2023 | Cycloset |
| Esperion Therapeutics, INC. | $265.36 | 2021-2024 | Nexletol |
| Mannkind Corporation | $244.99 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $244.08 | 2019-2023 | Farxiga |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $235.61 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $232.30 | 2019-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $229.69 | 2021-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $229.10 | 2020-2025 | Ubrelvy, Synthroid |
| Amgen INC. | $183.71 | 2019-2025 | Tepezza, Evenity |
| Radius Health, INC. | $178.02 | 2019-2024 | Tymlos |
| Insulet Corporation | $176.63 | 2019-2025 | Omnipod |
| Ibsa Pharma INC. | $160.42 | 2019-2025 | Tirosint, Tirosint, Licart |
| Madrigal Pharmaceuticals | $115.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Avvisto Therapeutics, LLC | $111.98 | 2024-2025 | Cycloset |
| Janssen Pharmaceuticals, INC | $104.06 | 2019 | |
| Neurocrine Biosciences, INC. | $82.72 | 2024-2025 | |
| Renalytix Ai, INC. | $78.15 | 2022 | |
| Nevro Corp. | $77.13 | 2022-2024 | Senza |
| Eusa Pharma (US) LLC | $76.44 | 2022 | |
| Ascendis Pharma Endocrinology INC | $66.21 | 2025 | Yorvipath |
| Astellas Pharma US INC | $51.56 | 2023-2025 | Veozah |
| Senseonics, Incorporated | $50.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $46.77 | 2020-2024 | Crysvita |
| Medtronic, INC. | $46.71 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $46.56 | 2019-2021 | |
| Cequr Corporation | $45.57 | 2024 | Cequr Simplicity |
| Antares Pharma, INC. | $43.80 | 2020-2023 | Tlando, Xyosted, Nocdurna |
| Shire North American Group INC | $42.95 | 2019 | |
| Companion Medical, INC. | $40.92 | 2019 | |
| Acerus Pharmaceuticals Corporation | $39.04 | 2020-2021 | |
| Vivus LLC | $38.37 | 2021-2023 | Qsymia |
| Sequel Med Tech, LLC | $37.34 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $33.51 | 2019 | |
| Intuity Medical INC | $28.18 | 2022 | |
| Pfizer INC. | $24.13 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $23.94 | 2025 | Imcivree |
| Echosens North America, INC. | $22.48 | 2023 | Fibroscan |
| Roche Diabetes Care, INC. | $21.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $19.53 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.66 | 2019 | |
| Horizon Therapeutics Plc | $18.44 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.92 | 2020 | |
| Currax Pharmaceuticals LLC | $14.68 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Troya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.